Know Cancer

forgot password

A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors

Phase 1
18 Years
Open (Enrolling)
Advanced Solid Tumors, Locally Advanced or Metastatic Breast or Colorectal Cancer

Thank you

Trial Information

A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors

This is a Phase Ib, open-label, multi-center, dose-escalation study of orally administered
tivozanib in combination with capecitabine to approximately 24 subjects with advanced solid
tumors and, in the expanded MTD cohort, subjects with locally advanced or metastatic breast
or colorectal cancer. This study is designed to evaluate the safety, tolerability,
dose-limiting toxicities, maximum tolerated dose, pharmacokinetic, and antineoplastic
activity. The number of cohorts evaluated and the maximum doses to be administered will
depend upon the observed tolerability. Dose level "0", tivozanib HCl 1.5 mg and capecitabine
1000 mg/m² BID, is the starting dose level. Once assigned to a cohort, each subject will
continue to be treated at the same dose level and schedule throughout the course of the

Inclusion Criteria:

1. Age 18 years or older, of either sex, and of any race.

2. Histologically or cytologically confirmed solid tumor malignancy.

3. Dose escalation cohorts: Advanced solid tumor malignancy (locally advanced or
metastatic) that has recurred or progressed following standard therapy or for which
no standard therapy currently exists, or for which subject is not a candidate for -
standard therapy, or is unwilling to undergo standard therapy.

4. MTD expansion cohort: Subjects must have locally advanced or metastatic breast or
colorectal cancer with or without prior systemic therapy.

5. ECOG performance ≤ 2 (Appendix B) and life expectancy ≥ 3 months.

6. Disease that is not amenable to curative surgical intervention, due to either
non-resectability of the tumor or medical contraindications.

7. Subjects enrolled in the MTD expansion cohort must have measurable disease according
to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0.

8. At least 4 weeks since :

• Vascular endothelial growth factor (VEGF) or VEGF receptor directed therapy

- Chemotherapy (6 weeks since prior mitomycin C or nitrosoureas)

- Immunotherapy (eg, IL-2, IFN, etc.) or biological therapy (eg, monoclonal

- Investigational agents

9. At least 2 weeks since:

- Systemic hormonal therapy (with the exception of hormone replacement therapy or
low dose steroid therapy as described in Drugs and Treatments to be Excluded)

- Herbal preparations (including daily multivitamin/mineral supplements containing
herbal components)

10. At least 2 weeks since prior radiotherapy to ≤ 25% of bone marrow, or at least 4
weeks since prior radiotherapy to > 25% of bone marrow.

11. If female and of child bearing potential, documentation of negative pregnancy test
prior to enrollment.

12. Sexually active pre-menopausal female subjects (and female partners of male subjects)
must use adequate contraceptive measures, while on study and for 30 days after the
last dose of study drug. All fertile subjects (and their partners) must agree to use
a highly effective method of contraception. Effective birth control includes (a) IUD
plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male
or female condoms, diaphragms, and spermicides (creams or gels that contain a
chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may
be affected by cytochrome P450 interactions, and are not considered effective for
this study.)

13. Adequate hematologic function as evidenced by Hg ≥ 9g/dL, WBC ≥ 3000 per mm3, ANC ≥
1500 per mm3 and platelet count ≥ 100,000 per mm3.

14. Adequate hepatic function as evidenced by a serum bilirubin level ≤1.5 × ULN (except
with known Gilbert's Syndrome) and serum AST/ALT levels ≤2.5 × ULN (or ≤5 × ULN for
subjects with known hepatic metastasis).

15. Adequate renal function as evidenced by a serum creatinine level ≤ 1.5 × ULN
(subjects with a serum creatinine level >1.5 x ULN with a calculated creatinine
clearance > 50 mL/min according to Cockcroft-Gault equation will be eligible).

16. Proteinuria ≤3+ by urinalysis or urine dipstick (subjects with proteinuria >3 + may
undergo a 24-hour urine protein and will be eligible if protein is <2 g/24hrs)

17. Adequate coagulation parameters: PTT ≤ 1.5 x ULN and INR ≤ 1.5

18. Ability to give written informed consent and comply with protocol requirements.

Exclusion Criteria:

- 1. Primary CNS malignancies or CNS metastases; subjects with previously treated brain
metastasis will be allowed if the brain metastasis has been stable without steroid
treatment for at least 3 months following prior treatment (radiotherapy or surgery).
Subjects with symptoms of CNS metastases or history must have a CT or MRI scan
including the brain during Screening.

2. Significant cardiovascular disease, including:

• Active clinically symptomatic left ventricular failure

- Uncontrolled hypertension: Systolic blood pressure > 140 mmHg or diastolic blood
pressure >90 mmHg on 2 or more antihypertensive medications. Note: Initiation or
adjustment of antihypertensive medication(s) is permitted during the screening
period, in order to control a subject's BP prior to initiating treatment. Blood
pressure must be re-assessed on two occasions that are separated by a minimum of
1 hour. The SBP / DBP values from each blood pressure assessment must be ≤
140/90 mmHg in order for a subject to be eligible for the study

- Myocardial infarction, severe or unstable angina within 6 months prior to
administration of first dose of study drug

- History of serious ventricular arrhythmia (ie, ventricular tachycardia or
ventricular fibrillation)

- Cardiac arrhythmias requiring anti-arrhythmic medications

- History of coronary or peripheral artery bypass graft within 6 months

3. Significant thromboembolic or vascular disorders within 6 months prior to
first dose of study drug; this does NOT include catheter-related thrombosis.
Significant thromboembolic or vascular disorders include but are not limited to:

- Deep vein thrombosis

- Pulmonary embolism

- Cerebrovascular accident (CVA) or transient ischemic attack (TIA)

- Symptomatic peripheral vascular disease

4. Subjects with non-healing wounds, active peptic ulcers, or unhealed bone

5. Known dihydropyrimidine dehydrogenase (DPD) deficiency.

6. Known hypersensitivity to fluoropyrimidine therapy or to 5-fluorouracil.

7. Known inability to tolerate capecitabine (Xeloda®) due to unacceptable

8. Serious active infection, (including active Hepatitis B or Hepatitis C) or
infection requiring parenteral antibiotics.

9. Inadequate recovery from any prior surgical procedure or major surgical
procedure within 4 weeks prior to administration of first dose of study drug.

10. Significant bleeding disorders within 6 months prior to first dose of study
drug, including but not limited to:

- Hematemesis, hematochezia, melena or other gastrointestinal bleeding

- Hemoptysis or other pulmonary bleeding

- Hematuria or other genitourinary bleeding

11. Currently active second primary malignancy, including hematologic
malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than
non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical
cancer and ductal or lobular carcinoma in situ of the breast. Subjects are not
considered to have a currently active malignancy if they have completed
anti-cancer therapy and have been disease free for >2 years.

12. Pregnant or lactating females.

13. Known concomitant genetic or acquired immune suppression disease such as

14. Centrally located lung cancer, or evidence of solid tumor invading major
blood vessels on imaging.

15. Malabsorption, uncontrolled vomiting or diarrhea, or any disease
significantly affecting gastrointestinal function that could interfere with
absorption of study drugs, or inability to swallow oral drugs.

Drugs and Treatments to be Excluded

1. Chemotherapy, biological therapy (including cytokines, signal transduction
inhibitors, monoclonal antibodies), immunotherapy or any other therapy for solid

2. Systemic hormonal therapy, with the exception of:

- Hormonal therapy for appetite stimulation or contraception

- Nasal, ophthalmic, inhaled and topical steroid preparations

- Androgen suppression therapy for non-metastatic prostate carcinoma

- Hormone replacement therapy for conditions such as adrenal insufficiency,
hypothyroidism, diabetes, etc.

- Low-dose maintenance steroid therapy (equivalent of prednisone ≤ 10 mg/day) for
other conditions

3. Treatment with radiotherapy (limited radiotherapy involving ≤ 25% of bone marrow may
be allowed for palliative purposes after consultation with the medical monitor.
Treatment with study drugs (tivozanib and capecitabine) must be stopped during

4. Herbal preparations/supplements (including daily multivitamin/mineral supplement
containing herbal components).

5. Treatment with full dose oral anticoagulants such as warfarin, acenocoumarol,
fenprocoumon, or similar agents. If previously receiving these types of agents, a
minimum washout of 1 week and documented INR of ≤ 1.5 will be required prior to start
of therapy. Full dose anticoagulation with low molecular weight heparin or
unfractionated heparin administered subcutaneously is allowed. Low dose oral
anticoagulation (eg, 1-2 mg/day warfarin) is allowed provided INR remains ≤ 1.5
during the study.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda®) to subjects with advanced solid tumors

Outcome Description:

Assessment of any dose-limiting toxcities

Outcome Time Frame:

daily for 6 weeks

Safety Issue:


Principal Investigator

Shefali Agarwal, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

AVEO Pharmaceuticals, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

November 2010

Completion Date:

December 2013

Related Keywords:

  • Advanced Solid Tumors
  • Locally Advanced or Metastatic Breast or Colorectal Cancer
  • AV-951
  • tivozanib
  • capecitabine (Xeloda®)
  • Colorectal Neoplasms
  • Neoplasms



Phoenix, Arizona  85012
Miami, Florida  33176
Nashville, Tennessee  37203-1632